![Michael K. Brawer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael K. Brawer
Nessuna posizione attualmente
Storia della carriera di Michael K. Brawer
Precedenti posizioni note di Michael K. Brawer
Società | Posizione | Inizio | Fine |
---|---|---|---|
MDXHEALTH SA | Direttore Tecnico/Scientifico/R&S | 06/09/2017 | 14/12/2018 |
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Direttore Tecnico/Scientifico/R&S | 01/04/2003 | 02/11/2007 |
Northwest Prostate Institute | Direttore/Membro del Consiglio | - | - |
MYRIAD GENETICS, INC. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Michael K. Brawer
University of California, Los Angeles | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Belgio | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MDXHEALTH SA | Health Technology |
MYRIAD GENETICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Northwest Prostate Institute |
- Borsa valori
- Insiders
- Michael K. Brawer
- Esperienza